Professional article
Open access

Changement majeur dans la prise en charge de l’asthme

Published inRevue médicale suisse, vol. 18, no. 797, p. 1788-1791
Publication date2022-09-28

According to the latest recommendations, there is no longer place for the use of short-acting beta-2 agonist alone in chronic asthma treatment, due to an increased risk of severe exacerbations and exacerbation-related mortality. Current management of asthma is based on the use of inhaled corticosteroids in combination with formoterol as maintenance and as rescue treatment, thanks to the rapid and prolonged action of formoterol. General practitioners must evaluate, with the patient's collaboration, the treatable factors linked to poor asthma control. They should provide patients with a written treatment plan in order to help patients recognize and manage asthma exacerbation. The place of the pulmonary specialist is currently reserved for the advanced stages of the disease and in case of diagnostic doubt.

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / diagnosis
  • Asthma / drug therapy
  • Bronchodilator Agents / therapeutic use
  • Ethanolamines / therapeutic use
  • Formoterol Fumarate / therapeutic use
  • Humans
Citation (ISO format)
AKHMETOVA, Leïla et al. Changement majeur dans la prise en charge de l’asthme. In: Revue médicale suisse, 2022, vol. 18, n° 797, p. 1788–1791. doi: 10.53738/REVMED.2022.18.797.1788
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/30/2022 6:00:00 AM
First validation09/30/2022 6:00:00 AM
Update time03/16/2023 8:02:44 AM
Status update03/16/2023 8:02:43 AM
Last indexation04/05/2024 2:17:03 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack